Bavarian Nordic
The answer first
Does Bavarian Nordic beat the market?
Yes, Bavarian Nordic has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 93% of Nordic stocks
- Quality78
- Value55
- Trend92
No. 6 of 195 in healthcare
Expectations in the price
Moderate expectations
For the share to return about 9% a year from today's price, the cash Bavarian Nordic keeps must grow about 7% a year for 10 years.
Max for seven days
Follow Bavarian Nordic with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Bavarian Nordic
Your first answer is free, no account needed.
Do you own Bavarian Nordic, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Bavarian Nordic and a few more. Free, no card.
Super Stock+44.6%In short
- Bavarian Nordic has risen 35.8% over the past year, including dividends.
- Overall, Bavarian Nordic ranks better than 93% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 66.0%. The price is 39.5% below its peak now.
What do analysts think of Bavarian Nordic?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 93% of Nordic stocks.
No. 6 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 59 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.01
- Asset turnoverSales divided by everything the company owns0.42
- Return on equityProfit divided by equity+6.6%
- Cash conversionOperating cash flow divided by profit1.15
The ranking is built on equity ratio, ROA and how steadily profit grows.
Medium Fair price: about the same as a typical Nordic stock.
No. 42 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity1.3
- P/SPrice divided by sales2.9
- P/EPrice divided by earnings20.2
- P/CFPrice divided by operating cash flow17.1
The ranking is built on P/E, P/B and P/S.
High Tailwind in the share price: it has risen more than most over the last year.
No. 20 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+16.0%
- 6 months+23.4%
- 9 months+26.7%
- 12 months+35.8%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Bavarian Nordic
14 funds we follow own Bavarian Nordic. The share is how much of the fund the stock makes up.
- Norway3
- Sweden5
- Denmark6
- 1 ETF
- Protean Aktiesparfond Norden ASweden · Protean1.7%
- BIX Danske Aktier Indeks ADenmark · BIX0.8%
- BIX Danske Aktier Indeks Akk ADenmark · BIX0.8%
- Danske Invest Danmark IndeksDenmark · Danske Invest0.8%
- Nordnet Indeksfond Danmark ASweden · Nordnet0.7%
- Xact KapitalforvaltningDenmark · XACT · ETF0.7%
- Sydinv Indeks Danmark A DKKDenmark · Sydinvest0.5%
- Wealth Inv I&T Nord AktLargeCaDenmark · Wealth Invest0.5%
Show all 14
- Handelsbanken Norden Ind Crit (A1 NOK)Sweden · Handelsbanken0.3%
- Alfred Berg Nordic Index R (SEK)Norway · Alfred Berg0.1%
- DNB Norden Indeks ANorway · DNB0.1%
- KLP AksjeNorden IndeksNorway · KLP0.1%
- Handelsbanken Gl Småbolag I Crit A9 EURSweden · Handelsbanken0.0%
- Handelsbanken Gl Småbolag Ind Cri A1 NOKSweden · Handelsbanken0.0%
From the funds' latest known holdings.
About Bavarian Nordic
Bavarian Nordic is a company in healthcare, listed on Nasdaq Copenhagen. The share trades in DKK. It has around 1,700 employees.
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses.


See the full analysis of Bavarian Nordic.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card